Background The interpretation of relative vaccine effectiveness (rVE) of improved influenza
vaccines is complex. Estimation of burden averted is useful to contextualise their potential …

Background The present study aims to evaluate the cost-effectiveness of extending the pre-
2013 influenza immunisation programme for high-risk and elderly individuals to those at low …

Background For the last 17 years, the UK has employed a routine influenza vaccination
programme with the aim of reducing the spread of seasonal influenza. In mid‐2000, the …

Background Influenza vaccine policies that maximise health benefit through efficient use of
limited resources are needed. Generally, influenza vaccination programmes have targeted …

Background Standard dose influenza vaccine provides moderate protection from infection,
but with lower effectiveness among the elderly. High dose and adjuvanted vaccines (HD-TIV …

Background The 2022/23 influenza season in the United Kingdom saw the return of
influenza to prepandemic levels following two seasons with low influenza activity. The early …

Background: In the United Kingdom (UK), a cell-based quadrivalent influenza vaccine (QIVc)
and a recombinant vaccine (QIVr) are recommended for eligible adults under 65 years. The …

Please cite this paper as: Kelly et al. Moderate influenza vaccine effectiveness with variable
effectiveness by match between circulating and vaccine strains in Australian adults aged 20 …

Objectives A large RCT (FIM12) and several real world studies have shown trivalent
influenza vaccine high dose (TIV HD) to be more effective than standard dose trivalent …

It is important to consider the value for money offered by existing elderly influenza
vaccination programs, particularly as doubts persist about the magnitude of the effectiveness …